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PathogenesisGenetic discoveries in ALS have a signiﬁcant impact on deciphering molecular mechanisms of motor neuron
degeneration. The identiﬁcation of SOD1 as the ﬁrst genetic cause of ALS led to the engineering of the SOD1
mouse, the backbone of ALS research, and set the stage for future genetic breakthroughs. In addition, careful
analysis of ALS pathology added valuable pieces to the ALS puzzle. From this joint effort, major pathogenic
pathways emerged. Whereas the study of TDP43, FUS and C9ORF72 pointed to the possible involvement of
RNA biology in motor neuron survival, recent work on P62 and UBQLN2 refocused research on protein
degradation pathways. Despite all these efforts, the etiology of most cases of sporadic ALS remains elusive.
Newly acquired genomic tools now allow the identiﬁcation of genetic and epigenetic factors that can either
increase ALS risk or modulate disease phenotype. These developments will certainly allow for better disease
modeling to identify novel therapeutic targets for ALS. This article is part of a Special Issue entitled: Neuromuscular
Diseases: Pathology and Molecular Pathogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis is an adult onset, fatal neurodegenera-
tive disorder involving the large motor neurons of the brain and the
spinal cord. It is clinically characterized by progressive paralysis and
eventual death from respiratory failure within three to ﬁve years. ALS
is in themain a sporadic disease but about 10% of ALS cases are familial.
SOD1 was the ﬁrst gene to be discovered about two decades ago, but in
the last ﬁfteen years, a number of new ALS causing genes have been
discovered (Table 1). These genes can play an important role in our
understanding of the pathogenesis of familial and sporadic ALS.2. Clinical features and diagnosis
Progressive puremotorweakness starting focally is themost distinc-
tive clinical feature of ALS. The disease starts with limb weakness in
about two-thirds of patients, often preceded by cramps, andwith bulbar
weakness causing dysarthria and dysphagia in the remaining one-third.
In rare instances, cognitive impairment, behavioral disturbances or
early respiratory failure can be the initial manifestation of ALS. The
characteristic combination of upper and lowermotor neuron dysfunction
is usually evident on neurological examination with the presence of
weakness, atrophy and fasciculations together with hyper-reﬂexia anduscular Diseases: Pathology and
1426, Chicago, IL 60611, USA.
-Driss).increased tone in the same motor segment and not infrequently an
extensor response to plantar stimulation. Sensory ﬁndings are minimal
or absent. Relentless, the disease contiguously spreads to other body
parts and eventually to respiratorymuscles leading to death fromrespira-
tory failure within 30 months on average [1]
The diagnosis of ALS is clinical, based on the history and physical
examination showing progressive upper and lower motor neuron
dysfunction. It is usually supported by electrophysiological studies and
neuroimaging and laboratory tests to excludemimickers. The El Escorial
criteria have been developed to standardize the diagnosis for clinical
research [2].
Familial ALS is more easily identiﬁed when there is a positive family
history; however, familial ALS may present as sporadic disease on
account of incomplete penetrance or incomplete family history. In the
absence of family history, an early age of onset, atypical rapid or slow
disease progression, pure lower motor neuron presentation or the
presence of dementia may alert to a familial etiology.
3. Update in the pathogenesis of familial ALS
The initial paradigm shift in approaching ALS pathogenesis, although
recently recognized [3], occurred about 30 years ago when the tools of
molecular genetics were applied to ALS. This effort led to the identiﬁca-
tion of theﬁrst ALS gene: superoxidedismutase 1 (SOD1),which accounts
for 20% of familial ALS cases [4–7], and turned the attention to hereditary
ALS as a means to investigate motor neuron degeneration.
SOD1 catalyzes the dismutation of superoxide radicals and protects
the cell against reactive oxygen species. More than 160 mutations in
SOD1 have been reported. Almost all are dominant missense mutations
Table 1
Causative ALS genes.
Gene symbol Locus Function Phenotype
SOD1 21q22 Superoxide metabolism AD-ALS/ALS1
TARDBP 1p36 RNA metabolism AD-ALS/ALS10, ALS-FTD
FUS 16p11 RNA metabolism AD-ALS/ALS6, ALS-FTD
OPTN 10p13 Many functions including membrane and vesicular trafﬁcking AD & AR-ALS/ALS12
VCP 9p13 Ubiquitinated protein trafﬁcking Autophagosme maturation AD-ALS/ALS14, ALS-FTD, IBMPFD
SQSTM1 5q35 Protein degradation AD-ALS, ALS-FTD, Paget's disease of bone
UBQLN2 Xp11 Protein degradation X-linked adult and juvenile ALS/ALS15, ALS-Dementia
C9ORF72 9p21 Unknown AD & sporadic-ALS/ALS-FTD
PFN1 17p13 Actin polymerization AD-ALS
680 S. Ajroud-Driss, T. Siddique / Biochimica et Biophysica Acta 1852 (2015) 679–684and account for 20% of familial ALS and for 2%–3%of apparently sporadic
cases (www.alsod.org). The A4V mutation is the most common
mutation in North America, followed by the I113T mutations [8]. Our
current understanding of the pathogenic role of mutant SOD1 comes
primarily from the study of transgenic rodents overexpressing mutant
SOD1 and in particular from the G93A mouse model [9] as it recapitu-
lates many features of the human SOD1 type disease. Although the
exact toxic mechanism of SOD1mutations is not completely elucidated,
themutant protein ismisfolded and gainsmany toxic functions that can
cause endoplasmic reticulum (ER) stress and include: overloading the
unfolded protein response, mitochondrial dysfunction and disruption
of axonal transport. Mutant SOD1 forms aggregates through an oxida-
tion-mediated mechanism and recruit wild-type SOD1 by crosslinking
of intermolecular disuliﬁde bonds [10]. Inclusions containing these
aggregates are found in the lower motor neuron and are a prominent
pathological feature of human familial ALS due to SOD1 mutations and
in the SOD1 mouse models [11–13]. Demetalled and unfolded apoform
of SOD1 enters the intermembrane space of the mitochondria, where it
is refolded by the chaperone of superoxide dismutase (CCS), copper and
zinc ions are acquired and intermolecular disulphide bonds form
between cysteine 57 and cysteine 146 [10,14]. In the SOD1 mouse
models (G93A, L126X and A4V), the apoprotein forms intermolecular
covalent bonds in the intermembrane space of the mitochondria,
heralding the onset of symptoms. This is particularly notable because
the A4V mice never becomes symptomatic until crossbred with mice
overexpressing wild-type SOD1, and the onset of symptoms coincides
with the formation of insoluble aggregates consisting of apo SOD1
with intermolecular covalent bond formation [10,14]. Not only mutant
SOD1 but wild-type SOD1 has also been proposed to undergo post-
translational modiﬁcations that can cause misfolding [15]. Using
conformation-speciﬁc antibodies, misfolded wild-type SOD1 has been
reported in the spinal cord of sporadic ALS patients and in non-SOD1
familial ALS but not in controls, implicatingwild-type SOD1 aggregationTable 2
Other genes causing ALS or ALS-like syndromes.
Gene Locus Function Phenotype
ALSIN 2q33 Vesicle trafﬁcking AR-Juvenile ALS/ALS2/PLS, infantile
onset spastic paraplegia
SETX 9q34 RNA/DNA helicase AD-juvenile ALS/ALS4
AR-ataxia with oculomotor apraxia
VAPB 20q13 Vesicle trafﬁcking AD-ALS/ALS8, AD-distal SMA
DCTN1 2p13 Axonal transport AD-ALS, PMA
ANG 14q11 Hypoxia responsive
ribonuclease
AD-ALS/ALS9
CHMP2B 3p11 Vesicle trafﬁcking AD-ALS, ALS-FTD
FIG4 6q21 Vesicle trafﬁcking AD-ALS/ALS11, PLS, CMT4J
DAO 12q24.11 Unknown AD-ALS
ATXN2 12q24.12 Unknown AD-ALS/ALS13, SCA2
hnRNPA2B1 7p15 RNA metabolism AD-ALS, multisystem
proteinopathy
hnRNPA2A1 12q13 RNA metabolism AD-ALS, multisystem
proteinopathyin the pathogenesis of sporadic ALS [16,17]. Following the discovery of
SOD1-familial ALS, several other genes causing ALS or ALS-like
syndromes were unraveled (Table 2), starting with the gene for ALS2
coding the protein ALSIN that was discovered in 2001 [18]. A major
step forward was the discovery of TAR DNA-binding protein (TDP-43/
TADBP) in 2006 as a major component of ubiquitinated inclusions in
ALS and subsequently in other neurodegenerative diseases [19]. ALS
families were then screened and mutations in TARDBP were also
found to cause familial ALS [20]. This important discovery provided a
direct pathogenic link between TDP43 and sporadic ALS similar to the
role of β-amyloid precursor protein in Alzheimer's disease and
α-synuclein in Parkinson's disease [20]. TDP43 is a DNA/RNA binding
protein involved in many cellular functions such as transcription and
splicing regulation, mRNA stability and microRNA processing [21,22].
TDP43 is primarily a nuclear protein, but after acute neuronal injury,
TDP43 translocates to the cytoplasm and forms stress granules that
dissolve after recovery, suggesting that TDP43 shuttles between the
nucleus and cytoplasm as a response to injury [23]. In the cortex of
ALS and FTD patients, TDP43 is phosphorylated, ubiquitinated and
cleaved, forming 20–25 kDa C-terminal insoluble fragments that
aggregates in the cytoplasm with loss of the normal TDP43 nuclear
staining in a sizable minority of neurons [19]. Over the years, several
cell and transgenic animal models of TDP43 have been developed
from yeast, zebra ﬁsh, drosophila, mice and rats. Although these animal
models do not exactly replicate an ALS-like phenotype, most suggested
that either the loss of nuclear or cytoplasmic TDP43 function or the gain
of new toxic function through the sequestration of essential proteins in
the aggregates plays an important role in neuronal degeneration.
Recently, TDP43 was also found to play a role in the axonal transport of
certain target mRNAs into distal neuronal compartments. ALS-causing
mutations in TDP43 impaired axonal trafﬁcking of these target mRNA
in Drosophila, in mouse cortical neurons and in ALS patients' motor
neurons derived from induced pluripotent stem cells, implicating the
loss of this new cytoplasmic function in the pathogenesis of ALS [24].
Shortly after the discovery of TDP43 mutations causing familial ALS,
mutations in fused in sarcoma/translocated in liposarcoma (FUS/TLS),
another RNA binding protein, were identiﬁed as causing about 4% of
familial ALS and rare sporadic ALS cases [25,26]. Like TDP43, FUS/TLS
is a nuclear proteinwithmanyRNA regulation andprocessing functions.
FUS immunoreactive inclusions are also found in sporadic ALS, in
non-SOD1 familial ALS and in ALS/dementia tissue [27].
It is presently not clear whether the role that TDP43 and FUS play in
motor neuron degeneration is through common or divergent pathways.
Prior genome-wide deletion and overexpression screens in yeast failed
to show signiﬁcant overlap in genetic modiﬁers of TDP43 and FUS
toxicity [28]. However, FUS was recently found to bind thousands of
human and mouse brain mRNAs, some shared with TDP43 [29]. The
depletion of FUS/TLS and TDP43 in human neurons, differentiated
from pluripotent stem cells, resulted in the down-regulation of long
intron containing TDP43 or FUS targets, some with important neuronal
functions, suggesting a common pathway for FUS and TDP43 in motor
neuron death [29]. In addition, using computational algorithms to
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and 10th, respectively) among RNA-binding proteins harboring a
canonical RNA recognition motif and a putative prion domain [30].
This prion-like domain has been recently implicated in TDP43 and FUS
toxic misfolding and aggregation in vitro [31].
This newly discovered role of RNAmetabolism and processing in the
pathogenesis of ALS was given a boost with the identiﬁcation of
mutations in C9ORF72. Expanded GGGGCC hexanucleotide repeats in
the ﬁrst intron of C9ORF72 were found to be the most common cause
of ALS and FTD (Fig. 1), responsible for about 30% of the familial and
5% of the sporadic ALS cases [32,33]. This gene encodes a protein of
unknown function and has provided additional evidence that impaired
RNA function is crucial for ALS. Intranuclear RNA foci, containing
expanded RNA transcripts, have been described in ALS and FTD tissue.
Similar to other repeat expansion diseases, it was recently demonstrated
that the toxicity of these RNA foci are length-dependent and sequester
speciﬁc RNA binding proteins such as hnRNP-H and multiple RNA
transcripts leading to signiﬁcant dysregulation of RNA processing [34].
Furthermore, this G4C2 expansion mutation can also be expressed in
both directions through repeat-associated non-ATG (RAN) translation,
producing sense and antisense C9-RAN proteins that are detected in the
P62-positive aggregate in C9ORF72-positive brains, linking RAN transla-
tion to ALS pathology [35,36].
The second paradigm shift in understanding ALS pathogenesis
occurred in 2011 [3] with the identiﬁcation of mutations in Ubiquilin
2 (UBQLN2) and Sequestosome 1 (SQSTM1 or P62) in patients with
familial ALS and ALS/dementia. Although UBQLN2 and SQSTM1 (P62)
contribute to a small subgroup of ALS cases, they are an important
component of the cytoplasmic inclusions not only in familial ALS tissues
but also in sporadic ALS, in FTD and in other degenerative diseases
including Alzheimer's (P62), Parkinson's (P62), Huntington's
(UBQLN2) and in muscle disease resembling inclusion body myopathy
(P62) [37–39].
UBQLN2 is amember of the ubiquilin family of proteins characterized
by the presence of an N-terminal ubiquitin-like domain (UBL) and a
C-terminal ubiquitin-association domain (UBA). This structure isFig. 1. Pathogenic mechanisms incharacteristic of the proteins that deliver ubiquitinated proteins to the
proteasome for degradation [40]. In addition, UBQLN2 also plays an
important role in autophagy. The UBL domain of ubiquilins mediates
both its associationwith autophagosomes and its protective effect against
starvation-induced cell death. Ubiquilins co-localize with
autophagosomes and bind LC3. Depletion of ubiquilins delays the deliv-
ery of autophagosomes to lysosomes, inhibiting autophagosome-lyso-
somal degradation [41]. ALS-causing mutations in UBQLN2 lead to
ubiquitin-mediated impairment of proteasomal degradation [42],
underscoring the role of UPS in the removal of misfolded and damaged
proteins.
Similar toUBQLN2, SQSTM1 (P62) also has aUBAC-terminal domain
and its N-terminal domains share considerable homology with the UBL
domain. P62, amultifunctional protein, also interactswithubiquitinated
proteins and acts as a cargo receptor for the degradation of
ubiquitinated proteins through both autophagic and proteosomal
pathways [43]. P62 mutations were identiﬁed in familial and sporadic
ALS [44,45], in FTD and in FTD-ALS [45,46]. Although the exact role
played by UBQLN2 and P62 in motor neuron degeneration has yet to
be elucidated, the presence of ubiquitin-P62-UBQLN2 positive
inclusions in brain and spinal cord tissues of all types of ALS [42] and
other degenerative disorders, directly implicates impaired protein
degradation pathways in the pathogenesis of ALS and highlights the
importance of these proteins in the ﬁnal common pathway of neuronal
degeneration.
Furthermore, mutations in P62 also cause about 25%–50% of familial
Paget's disease of bone, a disorder characterized by rapid bone turnover
[47]. Two additional proteins: optineurin (OPTN) and valosin-
containing protein (VCP) are also implicated in ALS/FTD and in Paget's
disease of bone. OPTN is involved in a variety of functions including
regulation of endocytic trafﬁcking, immune response, mitosis, NF-κB
signaling transduction and autophagy [48]. VCP belongs to the AAA +
protein family of ATPases, which have diverse biological functions;
among them, the possible delivery of degradation-destined
ubiquitinated protein to the 26S proteasome, autophagosome matura-
tion, placing it at the crossroad of protein degradation through bothmotor neuron degeneration.
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in P62, OPTN andVCP in ALS andPaget's disease of bone also suggests an
overlap between bonemetabolismandmotor neuron degeneration that
needs further investigation.
4. Update in the pathogenesis of sporadic ALS
Despite this enormous progress, the etiology of sporadic ALS
remains largely unknown. Going from the hypothesis that sporadic
disease may arise from complex interactions between genetic suscepti-
bility and environment, the scientiﬁc community turned to exploring
the genetic landscape of sporadic ALS to identify novel disease
mechanisms.
Several genome-wide association studies (GWAS) have been
performed in sporadic ALS identifying a variety of risk loci. Many of
themwere not replicated in large cohorts. Themost robust GWAS result
was the locus on chromosome 9p that contributed to the identiﬁcation
of C9ORF72. However, that study had an admixture of familial and
sporadic cases. UNC13A was also identiﬁed through GWAS to confer
susceptibility to ALS andmodulate survival [50,51]. UNC13A is a presyn-
aptic protein that regulates neurotransmitter release [50]. In mice, this
family of proteins is essential for synaptic vesicle priming. Mice lacking
UNC13A have disrupted glutamate signaling and morphological
abnormalities in spinal cord neurons and the neuromuscular junction
[52]. ELP3, a component of RNA polymerase II involved in RNA process-
ing, was found to be associated with ALS in three different populations.
Mutagenesis experiments in Drosophila and knock-down experiments
in zebra ﬁsh showed that ELP3 plays an important role in neuronal
biology [53]. Ataxin 2 was identiﬁed through a genetic screen in yeast
to modulate TDP43 toxicity. Intermediate repeat lengths, between 27
and 32 in Ataxin 2, were shown to predispose to ALS [54] with the
CAG repeat size between 29 and 33, conferring a higher risk (Santana
and Siddique, unpublished).
Besides identifying susceptibility loci, genome-wide association
studies were also used to discover genetic variants that can inﬂuence
ALS phenotype. A recent meta-analysis of the International Consortium
on Amyotrophic Lateral Sclerosis Genetics genome-wide association
samples identiﬁed a locus on chromosome 1p34 that modulates age of
disease onset. Other loci were also implicated in either modifying
survival (KIFAP3, UNC13A) or age of onset (VEGF, APOE…); however,
some of these studies have not been successfully replicated. Finally,
the paraoxonase gene cluster has been extensively examined in the
past years and has emerged as a potential risk factor; unfortunately,
the outcome of the GWAS examining its association with sporadic ALS
provided conﬂicting results [55,56].
5. Update in the pathology of familial and sporadic ALS
The pathology of ALS is characterized by the loss of pyramidal Betz
cells in the motor cortex as well as loss and degeneration of the large
anterior horn cells of the spinal cord and lower cranial motor nuclei of
the brainstem [57]. The degeneratingmotor neurons display intracellular
aggregates that form distinct ubiquitinated inclusions, the pathological
hallmark of the disease. Unveiling the molecular makeup of these inclu-
sions proved crucial in our understanding of the ALS pathomechanism.
Subsequent to the identiﬁcation of TDP43 as the major component
of the ubiquitinated inclusions in sporadic ALS [19] and in non-SOD1-
linked familial ALS, we showed that FUS-immunoreactive inclusions
were also present in spinal anterior horn neurons in all sporadic ALS
and in non-SOD1-familial ALS cases. The FUS-containing inclusions
were also immunoreactive with antibodies to TDP43, P62 and ubiquitin
[27]. OPTN immunoreactivity was also found in skein-like inclusions of
anterior horn neurons and their neurites in spinal cords of sporadic ALS
and in non-SOD1 familial ALS cases [58]. Finally, UBQLN2-positive
inclusions were identiﬁed in spinal cord sections of patients with
X-ALS and found to co-localize with ubiquitin, P62, TDP43, FUS andOPTN but not SOD1. UBQLN2 immunoreactivity was also observed in
spinal cord sections of sporadic ALS, ALS with dementia and in non-
SOD1 familial ALS [42], suggesting that SOD1 mutations may perform
their deleterious effects through distinct pathways. Widespread
UBQLN2-positive inclusions were also observed in the hippocampus of
ALS patients with dementia, including patients with expanded
hexanucleotide repeats in C9ORF72 [42].
The pathology of C9ORF72 is characterized by the presence of TDP43
inclusions in the shape of compact or granular neuronal cytoplasmic
inclusions in a minority of neurons containing ubiquitinated inclusions
of diffuse neuronal cytoplasmic staining, dystrophic neuritis, glial
cytoplasmic inclusions and variable numbers of neuronal intranuclear
inclusions. These inclusions are mainly found in pyramidal, frontal and
temporal cortex and hippocampus neurons [59]. In addition to TDP43
staining, a unique and characteristic feature of C9ORF72 is the presence
of cytoplasmic inclusions in the cerebellar granule cell layer, hippocampal
pyramidal neurons and neocortex that stain positively for UBQLN2, P62
and ubiquitin but are negative for TDP43 [60].
Although the direct link between the presence of these inclusions
andmotor neuron degeneration is not fully understood, themechanistic
dysfunction of UBQLN2 and P62 offers (currently) the most attractive
molecular mechanism of disease linked to etiology and pathology.6. Novel therapeutic approaches to ALS
Despite tremendous progress in the ﬁeld of genomics, ALS remains
an incurable disease. Phenotypic heterogeneity, divergent pathogenic
pathways and clinical trial methodologies may account for the negative
results obtained thus far and riluzole remains the only available therapy
with only a modest effect on disease progression. Nevertheless, many
compounds are either under development or in clinical trials.
Gene silencing through selective manipulation of RNA processing to
reduce toxic protein level is an exciting novel therapeutic opportunity
for familial ALS. Antisense oligonucleotide effectively decreased mutant
SOD1 expression and prolonged survival in the transgenic rats [61]. A
pilot study using intrathecal administration of antisense oligonucleo-
tides in patients with SOD1 familial ALS proved to be safe and well
tolerated [62], setting the stage for future gene silencing studies through
antisense approach, RNA interference or small molecules in all genetic
forms of ALS. Regenerative therapy using fetal human stem cells
delivered through intraspinal injections to 12 ALS patients reached its
safety endpoint [63] and a phase two clinical trial is underway. Finally,
the effect of autologous bone marrow-derived mesenchymal stem
cells (NurOwn) or human hepatocyte growth factor delivered through
intramuscular injections will soon be, or is currently being investigated.7. Conclusion
Signiﬁcant genetic progress has been accomplished in recent
decades with the discovery of several familial ALS genes. These genes
offered a unique opportunity to decipher the molecular mechanisms
of neuronal degeneration. Technological innovation in recent years
allowed for improved disease modeling, including the generation of in-
duced pluripotent stem cells and hastened therapy testing. The complex
genetic landscape of sporadic ALS and the presence of low-penetrance
loci that mimic sporadic ALS underscore the role that genomics still
have to play in our understanding of ALS pathogenesis and in develop-
ing rational therapies.Acknowledgement
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